These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
¨
|
Preliminary Proxy Statement
|
ý
|
Definitive Proxy Statement
|
¨
|
Definitive Additional Materials
|
¨
|
Soliciting Material Pursuant to Rule 14a-12
|
¨
|
Confidential, for the Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
(Name of Registrant as Specified In Its Charter)
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
ý
|
No fee required.
|
|
¨
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
|
|
|
(3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
|
|
|
(5)
|
Total fee paid
|
|
|
|
¨
|
Fee paid previously with preliminary materials.
|
|
¨
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
|
(1)
|
Amount Previously Paid:
|
|
|
|
|
(2)
|
Form, Schedule or Registration Statement No.:
|
|
|
|
|
(3)
|
Filing Party
|
|
|
|
|
(4)
|
Date Filed
|
|
|
|
![]() |
![]() |
|
Markos I. Tambakeras
Chair
|
||
![]() |
||
Patrick K. Decker
President & CEO
|
Date and Time:
|
Wednesday, May 10, 2017, at 11:00 a.m. ET
|
Place:
|
Xylem World Headquarters
1 International Drive, Rye Brook, New York 10573
|
Items of Business:
|
1.
Election of six members of the Xylem Inc. Board of Directors.
2.
Ratification of the appointment of Deloitte & Touche LLP as our independent registered accounting firm for 2017.
3.
Advisory vote to approve named executive officer compensation.
4.
Amendment to Articles of Incorporation to allow Shareholders to amend our By-laws.
5.
Transact such other business as may properly come before the meeting.
|
Record Date:
|
March 14, 2017
|
Mailing or Availability Date:
|
Beginning on or about March 28, 2017, this Notice of Annual Meeting and the 2017 Proxy Statement are being mailed and made available to shareholders of record as of March 14, 2017.
|
Voting by Proxy:
|
Your vote is important. You can vote your shares by Internet, by telephone or by completing and returning your proxy card or voting instruction form. Please see “Proxy Statement – Information About Voting” for details.
|
|
By Order of the Board of Directors,
|
|
![]() |
|
Claudia S. Toussaint
|
|
SVP, General Counsel & Corporate Secretary
|
Important Notice Regarding the Availability of Proxy Materials for the 2017 Annual Meeting:
|
Our 2017 Proxy Statement and Annual Report for the year ended December 31, 2016 will be available online at www.proxyvote.com and on our website at www.xyleminc.com under “Investors.”
|
Date and Time
|
Record Date
|
Location
|
May 10, 2017 at 11:00 a.m. ET
|
March 14, 2017
|
Xylem Inc. World Headquarters
1 International Drive
Rye Brook, New York 10573
|
Proposal
|
Board
Recommendation
|
Page
Reference
|
|
1
|
Election of 6 members of the Xylem Inc. Board of Directors
|
FOR
|
4
|
2
|
Ratification of the appointment of Deloitte & Touche LLP for 2017
|
FOR
|
9
|
3
|
Advisory vote to approve named executive officer compensation
|
FOR
|
11
|
4
|
Amendment to Articles of Incorporation to allow shareholders to amend the By-laws
|
FOR
|
12
|
•
Independent Chair
•
All Directors are independent except our CEO (90%)
•
Shareholder proxy access right
•
Regular engagement with shareholders
•
Senior executive & Director stock ownership guidelines
•
Restriction on the number of other boards Directors may serve on to avoid overboarding
•
Overall Board and committee meeting attendance of 98% in 2016
•
Board regularly reviews board size and composition, including diversity and tenure, as well as committee structure through its Nominating & Governance Committee
|
•
Executive officers are subject to clawback policy
•
Declassified Board phase-in will be complete in 2018
•
Shareholders have the right to call special meetings
•
No poison pill
•
Board & committees conduct annual self-assessments
•
Majority voting with a Director resignation policy for Directors in uncontested elections
•
Company policy prohibits executive officers and Directors from pledging and hedging Xylem stock
•
The Independent Directors hold regularly scheduled executive sessions of Board and each committee without Company management present
|
1
|
Xylem
2017 Proxy Statement
|
Proxy Access for Director Nominations
|
•
|
Ownership threshold:
3% of outstanding shares of our common stock, including certain loaned shares
|
•
|
Holding period:
Shares owned continuously for 3 years
|
•
|
Number of director nominees:
Two or up to 20% of our existing Board, whichever is greater
|
•
|
Nominating group size:
Up to 20 shareholders may group together to reach the 3% ownership threshold (counting certain groups of funds as one shareholder for these purposes)
|
•
A significant portion of our executive pay is performance-based and not guaranteed
•
Compensation for our named executive officers (“NEOs”) is aligned with shareholder interests through a balanced equity program (mix of restricted stock units, performance share units and stock options)
•
We conduct regular compensation benchmarking and an annual compensation risk assessment
•
We have a cap on our incentive compensation payouts
|
•
In 2016 we implemented a double-trigger change in control requirement for our long-term incentive awards
•
Our Leadership Development and Compensation Committee is advised by an independent compensation consultant
•
In 2016, as in prior years, we received strong support in our say-on-pay advisory vote (97%)
•
Our policy is to conduct an Annual Say-on-Pay shareholder vote
|
Xylem
2017 Proxy Statement
|
2
|
|
PAGE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
P
ROPOSAL
1 — E
LECTION OF
D
IRECTORS
|
Xylem's Board of Directors - Experience, Skills, Qualifications & Attributes
|
Leadership Experience
|
|
Operational Expertise
|
|
Diversity of Thought & Background
|
|
|
|
|
|
Governance Expertise
|
|
Strategic & Growth Experience
|
|
Global Experience
|
|
|
|
|
|
Technology & Innovation Experience
|
|
Water Industry Knowledge
|
|
Sales & Marketing Experience
|
|
|
|
|
|
Financial Expertise
|
|
Risk Management Experience
|
|
Talent Management Experience
|
Xylem
2017 Proxy Statement
|
4
|
Our Board of Directors recommends that you vote
FOR the election of each of the 2017 director nominees
|
2017 Director Nominees
|
|
|
|
|
|
Curtis J. Crawford, Ph.D.
_____________________
Director since 2011
_____________________
Age 69
_____________________
Independent
_____________________
Committees
l
Leadership Development & Compensation (Chair)
l
Finance, Innovation &
Technology
|
|
![]() |
|
Curtis J. Crawford, Ph.D. has served as President and Chief Executive Officer of XCEO, Inc. since 2003. XCEO is a consulting firm specializing in leadership and governance. From 2002 to 2003, he served as President and Chief Executive Officer of Onix Microsystems, a private photonics technology company. Dr. Crawford served as both Chief Executive Officer (1998 to 2001) and Chairman (1999 to 2001) of ZiLOG, Inc., and also has extensive executive experience with AT&T Corporation and IBM Corporation.
|
|
Dr. Crawford brings significant experience in technological innovation and leading high-technology companies to our Board. He also provides expertise in the area of corporate governance. He is the author of three books on leadership and corporate governance and has more than 20 years of board experience. In 2011, Dr. Crawford was awarded the B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors for his contributions to corporate governance and for having made a meaningful impact in the boardroom.
Public Company Boards
l
ON Semiconductor Corporation (1999-present); Chairman (1999-2002)
l
The Chemours Company (2015-present)
l
E.I. DuPont de Nemours and Company (1998-2015)
l
ITT Corporation (1996-2011)
l
Agilysys, Inc. (2005-2008)
|
|
|
|
|
|
Robert F. Friel
_____________________
Director since 2012
_____________________
Age 61
_____________________
Independent
_____________________
Committees
l
Nominating & Governance(Chair)
l
Audit
|
|
![]() |
|
Robert F. Friel has served as Chief Executive Officer of PerkinElmer, Inc., a multinational corporation focused on human and environmental health, since 2008. Mr. Friel joined PerkinElmer in 1999 and has held a variety of positions, including Executive Vice President and Chief Financial Officer, with responsibility for business development and information technology, in addition to his oversight of the finance function. Mr. Friel also served as President of Life and Analytical Sciences, and President and Chief Operating Officer.
|
|
From 1980 to 1999, he held several senior management positions with AlliedSignal, Inc., now Honeywell International Inc.
Mr. Friel brings extensive experience in global technology industries as well as his strategic, financial and board leadership experience to our Board.
Public Company Boards
l
PerkinElmer, Inc. (2006-present); Chairman (2009-present
)
l
NuVasive, Inc. (2016-present)
l
CareFusion, Inc. (2009-2015)
l
Fairchild Semiconductor, Inc. (2004-2009)
l
Millennium Pharmaceuticals, Inc. (2005-2008)
|
|||
|
5
|
Xylem
2017 Proxy Statement
|
|
|
|
|
|
Sten E. Jakobsson
_____________________
Director since 2011
_____________________
Age 68
_____________________
Independent
_____________________
Committees
l
Audit
l
Leadership Development & Compensation
|
|
![]() |
|
Mr. Jakobsson is the Former President and Chief Executive Officer of ABB AB, the Swedish subsidiary of ABB Ltd., a leading power and industrial automation company. During his nearly 40-year career at ABB, he held several key leadership positions, including Head of the North Europe Region and Executive Vice President of the Power Transmission and Distribution Segment. He retired from AAB in 2011. Mr. Jakobsson has served as Chairman of Power Wind Partners AB, a private company, since 2011.
|
|
In 2014 he was appointed Chairman of Luossavaara-Kiirunavaara Aktiebolag, a non-public company, where he has been a director since 2012.
Mr. Jakobsson brings to our Board extensive experience in managing global industrial organizations, including expertise in international sales, complex project execution and manufacturing operations.
Public Company Boards
l
Stena Metall AB (2006-present)
l
SAAB AB (2008-present)
l
FLSmidth & Co. A/S (2011-present)
|
|||
|
|
|
|
|
|
Steven R. Loranger
_____________________
Director since 2011
_____________________
Age 65
_____________________
Independent
_____________________
Committees
l
Audit
l
Nominating & Governance
|
|
![]() |
|
Steven R. Loranger served as Chairman, President and CEO of ITT Corporation, a global manufacturing company, from 2004 until October 2011. He served as interim Chief Executive Officer and President of Xylem Inc. from September 2013 until March 2014. Mr. Loranger served as Executive Vice President and Chief Operating Officer of Textron, Inc. from 2002 to 2004.
|
|
Mr. Loranger held executive positions at Honeywell International Inc. and its predecessor company, AlliedSignal, Inc. from 1981 to 2002, including serving as President and Chief Executive Officer of its Engines, Systems and Services businesses. Mr. Loranger is a Senior Advisor to the CEO of FlightSafety International and he serves on the Boards of the National Air and Space Museum, the Congressional Medal of Honor Foundation and the Wings Club.
Mr. Loranger brings an in-depth understanding of the Company’s operations, as well as valuable institutional knowledge to our Board. He has extensive operational and manufacturing experience with industrial companies.
Public Company Boards
l
Edwards Lifesciences Corporation (2016-present)
l
FedEx Corporation (2006-2014)
l
Exelis Inc. (2011-2013)
l
ITT Corporation (Chairman) (2004-2011)
|
|||
|
Xylem
2017 Proxy Statement
|
6
|
|
|
|
|
Surya N. Mohapatra Ph.D.
_____________________
Director since 2011
_____________________
Age 67
_____________________
Independent
_____________________
Committees
l
Finance, Innovation & Technology
l
Nominating & Governance
|
|
![]() |
Surya N. Mohapatra Ph.D. served as Chief Executive Officer and Chairman of Quest Diagnostics Incorporated, a leading provider of diagnostic information services from 2004 until 2012. Dr. Mohapatra joined Quest Diagnostics as Senior Vice President and Chief Operating Officer in 1999. Prior to joining Quest Diagnostics, Dr. Mohapatra was Senior Vice President and a member of the executive committee of Picker International, a worldwide leader in advanced medical imaging technologies, where he served in various executive positions during his 18-year tenure.
|
|
Dr. Mohapatra serves as a Director on the Board of Leidos, a science and technology company, and is a trustee of the Rockefeller University. He is also an Executive-in-Residence at Columbia Business School.
Dr. Mohapatra brings to the Board his extensive international business experience and wide-ranging operational and strategic knowledge. Dr. Mohapatra has a strong technical background with an emphasis on Six-Sigma quality and customer-focused business practices.
Public Company Boards
l
Leidos Holdings (2016-present)
l
Quest Diagnostics (2002-2012); Chairman (2004-2012)
l
ITT Corporation (2008-2011)
|
||
|
|
|
|
|
|
Jerome A. Peribere
_____________________
Director since 2013
_____________________
Age 62
_____________________
Independent
_____________________
Committees
l
Finance, Innovation & Technology
l
Nominating & Governance
|
|
![]() |
|
Jerome A. Peribere has served as President and Chief Executive Officer of Sealed Air, a global manufacturer of protective and specialty packaging for food and consumer goods, since 2013. He previously served as the President and Chief Operating Officer of Sealed Air.
|
|
From 1977 through 2012 Mr. Peribere held various leadership roles at The Dow Chemical Company (“Dow”), most recently as Executive Vice President of Dow and President and Chief Executive Officer, Dow Advanced Materials from 2009 through August 2012. Mr. Peribere currently serves on the Board of the SEI Center for Advanced Studies in Management at the Wharton School of the University of Pennsylvania.
Mr. Peribere brings extensive leadership, global operations, strategy and integration experience to the Board.
Public Company Boards
l
Sealed Air (2012-present)
l
BMO Financial Corporation (2007-2014)
|
|||
|
7
|
Xylem
2017 Proxy Statement
|
Directors Whose Term Expires in 2018
|
|
|
|
||
Patrick K. Decker
_____________________
Director since 2014
_____________________
Age 52
|
|
![]() |
|
Patrick K. Decker has served as President and Chief Executive Officer of Xylem since March of 2014. He joined Xylem from Harsco Corporation, a global industrial services company, where he was President and Chief Executive Officer since 2012. Prior to that, he served in a number of leadership roles for Tyco International’s Flow Control business, ultimately serving as President of Tyco Flow Control, a leader in industrial flow control solutions.
|
|
|
Mr. Decker is a member of the Bipartisan Policy Center’s Executive Council on Infrastructure as well as the Energy and Environment Committee of the Business Roundtable.
Earlier in his career, Mr. Decker held a number of progressively responsible financial leadership positions at Bristol-Myers Squibb Company, including nine years of service in Latin America and Asia. He started his career as an auditor for Price Waterhouse LLP, now PricewaterhouseCoopers, LLP. He currently serves on the advisory council for the Dean of the Kelley School of Business at Indiana University.
Mr. Decker brings valuable global leadership experience, expertise in business operations and finance and extensive knowledge of the water industry to the Board.
Public Company Boards
l
Harsco Corporation (2012-2014)
|
||
|
|
|
|
|
|
Victoria D. Harker
_____________________
Director since 2011
_____________________
Age 51
_____________________
Independent
_____________________
Committees
l
Audit (Chair)
l
Leadership Development & Compensation
|
|
![]() |
|
Victoria D. Harker is EVP and Chief Financial Officer of TEGNA, Inc. and former CFO of Gannett Co., Inc. TEGNA is the broadcasting and digital businesses company formed when Gannett split into two publicly traded companies in 2015. Prior to joining Gannett in 2012, Ms. Harker served as the CFO and President of Global Business Services of the AES Corporation.
|
|
Prior to joining AES in 2006, she held several key leadership roles including Acting Chief Financial Officer and Treasurer of MCI and Chief Financial Officer of MCI Group, a unit of World-Com Inc. Ms. Harker sits on the American University Advisory Council, and serves as a trustee on the Board of Visitors of the University of Virginia.
Ms. Harker brings to the Board extensive international business experience with a wide-ranging management and financial reporting background. Ms. Harker’s experience as a director for other public companies provides additional relevant experience in serving on our Board of Directors
.
Public Company Boards
l
Huntington Ingalls Industries (2012-present)
l
Darden Restaurants, Inc. (2009-2014)
|
|||
|
Xylem
2017 Proxy Statement
|
8
|
|
|
|
|
|
Markos I. Tambakeras
_____________________
Director since 2011
_____________________
Age 66
_____________________
Independent Chair
_____________________
Committees
l
Nominating & Governance
|
|
![]() |
|
Markos I. Tambakeras has served on our Board of Directors as Chairman since 2011. Mr. Tambakeras was Chairman, President and Chief Executive Officer of Kennametal, Inc. from 1999 until 2005 and President, Industrial Controls Business, for Honeywell Incorporated from 1995 to 1999.
He currently is Vice Chair of the Board of Make-A-Wish Foundation International.
|
|
Mr. Tambakeras serves on the Board of Trustees of Loyola Marymount University and has served for five years on the President’s Council on Manufacturing. He was previously the Chairman of the Board of Trustees of the Manufacturers Alliance/MAPI, which is the manufacturing industry’s leading executive development and business research organization.
Mr. Tambakeras brings strong strategic and global industrial experience to the Board, having worked in increasingly responsible positions for several manufacturing companies, including leadership positions in South Africa and the Asia-Pacific area. In addition to his Board leadership experience described above, Mr. Tambakeras has an extensive background in international operations.
Public Company Board Experience:
l
ITT Corporation (2001-2013)
l
Parker Hannifin Corporation (2005-2011)
l
Newport Corporation (2008-2009)
l
Kennamental, Inc. (1999-2006); Chairman (2002-2006)
|
|||
|
P
ROPOSAL
2 — R
ATIFICATION OF
A
PPOINTMENT OF THE
I
NDEPENDENT
R
EGISTERED
P
UBLIC
A
CCOUNTING FIRM
|
|
l
|
independence
|
l
|
peer review program
|
|
l
|
experience
|
l
|
report on quality
|
|
l
|
technical capabilities
|
l
|
appropriateness of fees charged
|
|
l
|
client service assessment
|
l
|
industry insight
|
|
l
|
responsiveness
|
l
|
PCAOB inspection results
|
9
|
Xylem
2017 Proxy Statement
|
|
2016
|
|
2015
|
||||
|
(In thousands)
|
||||||
Audit Fees (1)
|
$
|
6,681
|
|
|
$
|
7,445
|
|
Audit-Related Fees (2)
|
110
|
|
|
195
|
|
||
Tax Compliance Services
|
1,769
|
|
|
1,416
|
|
||
Tax Planning Services
|
420
|
|
|
415
|
|
||
Total Tax Services (3)
|
2,189
|
|
|
1,831
|
|
||
All Other Fees (4)
|
6
|
|
|
84
|
|
||
Total
|
$
|
8,986
|
|
|
$
|
9,555
|
|
(1)
|
Fees for audit services billed consisted of:
|
•
|
Audit of the Company’s annual financial statements and internal controls over financial reporting;
|
•
|
Reviews of the Company’s quarterly financial statements;
|
•
|
Statutory and regulatory audits, consents and other services related to SEC matters; and
|
•
|
Financial accounting and reporting consultations.
|
(2)
|
Fees for audit-related services consisted of:
|
•
|
Audits and other attest work related to subsidiaries (other than statutory audits) and employee benefit plans; and
|
•
|
Other miscellaneous attest services.
|
(3)
|
Fees for tax services consisted of tax compliance and tax planning services:
|
•
|
Tax compliance services are services rendered based upon facts already in existence or transactions that have already occurred, to document, compute, and review amounts to be included in tax filings; and
|
•
|
Tax planning services are services and advice rendered with respect to proposed transactions or services that alter the structure of a transaction to obtain an anticipated tax result. Such services consisted primarily of tax advice related to intra-group structuring.
|
(4)
|
Fees related to the Company’s subscription to research tools and assistance with identification of available grants in Europe
.
|
Xylem
2017 Proxy Statement
|
10
|
Our Board of Directors recommends that you vote FOR the ratification of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for 2017
|
P
ROPOSAL
3 — A
DVISORY
A
PPROVAL
OF
N
AMED
E
XECUTIVE
O
FFICER
C
OMPENSATION
|
•
|
alignment of executive and shareholder interests by providing incentives linked to key financial performance metrics, which the LDCC believes will help drive long-term shareholder value;
|
•
|
the ability for executives to achieve long-term shareholder value creation without undue business risk;
|
•
|
the creation of a clear link between an executive’s compensation and his or her individual contribution and performance;
|
•
|
the extremely competitive nature of the industries in which we operate and our need to attract and retain the most creative and talented industry leaders; and
|
•
|
comparability to the practices of peers in the industries in which we operate and other similar companies generally.
|
Our Board of Directors recommends that you vote FOR the
Advisory Vote to Approve Named Executive Officer Compensation
|
11
|
Xylem
2017 Proxy Statement
|
P
ROPOSAL
4 — Approval of an Amendment to the Company's Articles of Incorporation to Allow Shareholders to Amend the By-laws
|
Our Board recommends that you vote FOR the Amendment to the Company's Articles of Incorporation to Allow Shareholders to Amend the By-laws
|
Xylem
2017 Proxy Statement
|
12
|
We make a concerted effort to engage with shareholders at various times throughout the year to solicit their feedback on a range of topics including those related to governance and executive compensation.
|
13
|
Xylem
2017 Proxy Statement
|
Board/Committee
|
|
Examples of Areas of Risk Oversight
|
Board
|
l
|
Significant commercial and capital markets risks
|
l
|
Significant legal or reputational matters
|
|
l
|
Significant mergers and acquisitions
|
|
l
|
Competitive developments
|
|
Audit Committee
|
l
|
Oversight of overall risk assessment and risk management processes and policies
|
l
|
Accounting, controls and financial disclosures
|
|
l
|
Financial statements and financial risk exposures
|
|
l
|
Tax strategy and related risks
|
|
Finance, Innovation & Technology Committee
|
l
|
Capital spending
|
l
|
Financing strategies and liquidity
|
|
l
|
Technology and innovation
|
|
Leadership Development & Compensation Committee
|
l
|
Executive compensation philosophy and program design (as described in more detail under “Compensation Risk Oversight” on page 19)
|
l
|
Executive development and leadership
|
|
l
|
Succession planning for senior management
|
|
Nominating and Governance Committee
|
l
|
Compliance programs, including anti-corruption and environmental, health & safety
|
l
|
Cyber risk
|
|
l
|
Corporate governance
|
|
l
|
Sustainability
|
Xylem
2017 Proxy Statement
|
14
|
Independence:
All of our Directors are independent, with the exception of our CEO.
|
Board Diversity:
Our Board actively seeks to consider diverse candidates for membership on the Board, taking into account diversity in terms of viewpoints, professional experience, education and skills as well as race, gender and nationality.
|
Assessment of Board Effectiveness:
Each year our Nominating and Governance Committee initiates an assessment of the effectiveness of the Board and each of our committees. The Board assessment solicits each Director's opinion on a variety of topics, including the overall composition of the Board. In addition to a survey-style assessment, the Chair of the Nominating and Governance Committee holds one-on-one conversations with each Board member to solicit additional feedback. On a periodic basis (generally every three years) the Nominating and Governance Committee will also engage an independent third party consultant to meet with each Board member to assist with the qualitative assessment of the Board. The independent consultant presents the findings to the full Board and facilitates a robust discussion focusing on opportunities for improvement. The consultant also provides feedback to individual directors, as applicable. This periodic process most recently occurred in late 2015.
|
15
|
Xylem
2017 Proxy Statement
|
•
|
whether terms or conditions of the transaction are generally similar to those available to third parties;
|
•
|
the level of interest or benefit to the related party;
|
•
|
the availability of alternative suppliers or customers; and
|
•
|
the benefit to the Company.
|
BOARD MEETINGS
|
Site Visits:
We encourage our Directors to conduct site visits, and periodically hold meetings at one of our sites so that our Directors can meet with employees, customers and other stakeholders, and visit our facilities.
|
Xylem
2017 Proxy Statement
|
16
|
B
OARD
C
OMMITTEES
|
•
|
Determine the appointment, compensation, evaluation and termination of the independent auditors.
|
•
|
Review and discuss with management and the independent auditors the annual audited financial statements and quarterly financial statements of the Company.
|
•
|
Discuss policies with respect to risk assessment and risk management.
|
•
|
Review significant findings or unsatisfactory internal audit reports or audit problems or difficulties encountered by independent auditors in the course of the audit work.
|
•
|
Review major issues regarding the Company’s accounting principles and internal controls.
|
Xylem
2017 Proxy Statement
|
17
|
•
|
Review the Company’s technology and innovation strategy in the context of overall corporate strategy, goals and objectives.
|
•
|
Review the Company's financial strategies, capital structure, liquidity and credit rating.
|
•
|
Develop, review, update and recommend corporate governance principles to the Board of Directors.
|
•
|
Evaluate and make recommendations to the Board of Directors concerning the composition, governance and structure of the Board.
|
•
|
Determine the composition of Board committees, including the chairs.
|
•
|
Make recommendations to the Board of Directors concerning the qualifications, compensation and retirement age of Directors.
|
•
|
Oversee the business ethics and anti-corruption programs.
|
•
|
Administer the Board of Directors’ annual Board and committee self-assessment.
|
•
|
Identify, evaluate and propose nominees for election to the Board of Directors and conduct searches for prospective Board members.
|
•
|
Oversee specialty compliance programs, including environmental, health and safety, business continuity, trade compliance and cyber risk.
|
•
|
Review the Company’s sustainability programs and related activities.
|
Xylem
2017 Proxy Statement
|
18
|
•
|
Approve and oversee administration of the Company’s executive compensation program including incentive plans and equity-based compensation plans.
|
•
|
Set annual performance goals and strategic objectives for the CEO and evaluate CEO performance against such goals.
|
•
|
Approve individual compensation actions for executive officers.
|
•
|
Oversee the establishment and administration of the Company’s executive officer benefit programs and severance policies.
|
•
|
Oversee leadership development and succession planning for executive officers.
|
Compensation Element
|
|
Risk Mitigation Factors
|
Base Salary
|
l
|
Fixed component.
|
l
|
Represents a relatively small percentage of total compensation.
|
|
Annual
Incentive Plan
|
l
|
Determined based on multiple performance factors to align executives globally on key business priorities.
|
l
|
Regular assessment of the pay and performance relationship of Annual Incentive Plan performance targets and range of potential payouts to ensure appropriate pay for performance alignment.
|
|
l
|
Final payouts made after a validation process to confirm business results and applicable earned payout.
|
|
l
|
Capped performance scores and awards payable to any individual.
|
|
l
|
Payouts subject to clawback policy.
|
|
Long-Term Incentive Plan
|
l
|
LTIP awards valued and granted on the approval date.
|
l
|
Balanced mix of performance metrics (an internal absolute metric and an external relative metric) intended to ensure pay for performance based on Company goals and directly linked to delivering shareholder value.
|
|
l
|
Regular assessment of the pay and performance relationship of LTIP performance targets and range of potential payouts to ensure appropriate pay for performance alignment.
|
|
l
|
Re-pricing or exchange of stock options without shareholder approval prohibited.
|
|
l
|
Stock ownership guidelines for senior executives.
|
|
l
|
Payouts subject to clawback policy.
|
|
l
|
Strong insider trading policy, which prohibits the hedging and pledging of our common stock.
|
19
|
Xylem
2017 Proxy Statement
|
Xylem
2017 Proxy Statement
|
20
|
S
TOCK
O
WNERSHIP
OF
D
IRECTORS,
E
XECUTIVE
O
FFICERS
AND
C
ERTAIN
B
ENEFICIAL
O
WNERS
|
Name of Beneficial Owner
|
Total Shares
Beneficially Owned
(1)(2)
|
Percentage of
Class
|
|
Curtis J. Crawford
|
57,203
|
|
*
|
Patrick K. Decker
|
355,539
|
|
*
|
Robert F. Friel
|
11,264
|
|
*
|
Victoria D. Harker
|
15,062
|
|
*
|
Sten E. Jakobsson
|
10,986
|
|
*
|
Steven R. Loranger
|
315,586
(3)
|
|
*
|
Edward J. Ludwig
|
25,187
(4)
|
|
*
|
Surya N. Mohapatra
|
30,787
|
|
*
|
Jerome A. Peribere
|
9,892
|
|
*
|
Markos I. Tambakeras
|
54,596
(5)
|
|
*
|
Kenneth Napolitano
|
221,279
|
|
*
|
Shashank Patel
|
43,360
|
|
*
|
E. Mark Rajkowski
|
13,516
|
|
*
|
Colin R. Sabol
|
78,062
|
|
*
|
Claudia S. Toussaint
|
44,769
|
|
*
|
All Current Directors and Executive Officers as a Group (20 persons)
|
1,351,329
|
|
*
|
(1)
|
The shares shown includes the following vested but deferred RSUs: Robert F. Friel, 9,789 RSUs; Edward J. Ludwig, 9,983 RSUs; Surya N. Mohapatra, 1,355 RSUs; Jerome A. Peribere, 3,249 RSUs; and all directors as a group, 24,376.
|
(2)
|
The shares shown includes the following shares that directors and executive officers have the right to acquire within 60 days after January 31, 2017: Patrick K. Decker, 167,820 shares; shares; Kenneth Napolitano, 24,633 shares; Shashank Patel, 7,145 shares; E. Mark Rajkowski, 13,349; Colin Sabol, 19,244 shares; Claudia Toussaint, 13,314 and all directors and executive officers as a group, 256,753 shares
|
(3)
|
Includes 130,918 shares held by a family trust of which Mr. Loranger is the trustee and disclaims beneficial ownership.
|
(4)
|
Includes 6,085 shares of deferred phantom stock.
|
(5)
|
Includes 49,457 shares held by a family trust of which Mr. Tambakeras and his spouse are co-trustees and as to which Mr. Tambakeras disclaims beneficial ownership.
|
21
|
Xylem
2017 Proxy Statement
|
Name and Address of Beneficial Owner
|
Amount and Nature of Beneficial Ownership
|
Percent
of Class
|
BlackRock, Inc.
(1)
40 East 52
nd
Street
New York, New York 10022
|
11,733,704
|
6.50
|
Parnassus Investments
(2)
1 Market Street, Suite 1600
San Francisco, CA 94105
|
9,067,732
|
5.05
|
The Vanguard Group
(3)
100 Vanguard Boulevard
Malvern, Pennsylvania 19355
|
16,668,503
|
9.29
|
T. Rowe Price Associates, Inc.
(4)
100 Vanguard Boulevard
Malvern, Pennsylvania 19355
|
9,852,796
|
5.40
|
(1)
|
As of December 31, 2016, BlackRock, Inc. had sole voting power with respect to 10,085,815 shares and sole dispositive power with respect to 11,733,704 shares. The foregoing information is based solely on a Schedule 13G/A filed by BlackRock, Inc. with the SEC on January 26, 2017.
|
(2)
|
As of December 31, 2016, Parnassus Investments had sole voting power with respect to 9,067,732 shares and sole dispositive power with respect to 9,067,732 shares. This information is based solely on a Schedule 13G filed by Parnassus Investments with the SEC on February 14, 2017.
|
(3)
|
As of December 31, 2016, The Vanguard Group had sole voting power with respect to 284,780 shares, sole dispositive power with respect to 16,358,265 shares and shared dispositive power with respect to 310,238 shares. The foregoing information is based solely on a Schedule 13G/A filed by The Vanguard Group, Inc. with the SEC on February 10, 2017.
|
(4)
|
As of December 31, 2016, T. Rowe Price Associates, Inc. had sole voting power with respect to 2,690,150 shares and sole dispositive power with respect to 9.852,796 shares. The foregoing information is based solely on a Schedule 13G/A filed with the SEC on February 7, 2017.
|
Xylem
2017 Proxy Statement
|
22
|
Chief Executive Officer
|
5 X Annual Base Salary
|
Chief Financial Officer
|
3 X Annual Base Salary
|
Senior Vice Presidents
|
2 X Annual Base Salary
|
Directors
|
5 X Annual Cash Retainer
|
•
|
All Rule 10b5-1 plans must be pre-cleared by Xylem’s legal department.
|
•
|
A 10b5-1 plan may only be entered into during an open trading window and while the insider is not in possession of material non-public information.
|
•
|
No trades may occur for the first 30 days after entering into a 10b5-1 plan and no trading may occur until 60 days after elective termination of a 10b5-1 plan.
|
S
ECTION
16
(A)
B
ENEFICIAL
O
WNERSHIP
R
EPORTING
C
OMPLIANCE
|
23
|
Xylem
2017 Proxy Statement
|
Compensation Element
|
2016
|
2017
|
Standard Board Compensation
|
|
|
Annual Cash Retainer
|
$100,000
|
$100,000
|
Annual Equity Award
|
$120,000
|
$140,000
|
Board and Committee Chair Retainers
|
|
|
Independent Board Chair
|
$135,000
|
$135,000
|
|
($67,500 in cash and $67,500 in RSUs)
|
|
Audit Committee Chair
|
$17,000
|
$20,000
|
All other Committee Chairs
|
$12,000
|
$15,000
|
Xylem
2017 Proxy Statement
|
24
|
Name
|
Fees Earned or
Paid in Cash
($)
(1)
|
Stock
Awards
($)
(2)
|
Total
($)
|
Curtis J. Crawford
|
112,000
|
120,021
|
232,021
|
Robert F. Friel
|
112,000
|
120,021
|
232,021
|
Victoria D. Harker
|
117,000
|
120,021
|
237,021
|
Sten E. Jakobsson
|
100,000
|
120,021
|
220,021
|
Steven R. Loranger
|
100,000
|
120,021
|
220,021
|
Edward J. Ludwig
|
112,000
|
120,021
|
232,021
|
Surya N. Mohapatra
|
100,000
|
120,021
|
220,021
|
Jerome A. Peribere
|
100,000
|
120,021
|
220,021
|
Markos I. Tambakeras
|
167,500
|
187,514
|
355,014
|
(1)
|
Fees earned may be paid, at the election of the Director, in cash or deferred cash. Non-employee Directors may irrevocably elect deferral into an interest-bearing cash account or an account that tracks the performance of Xylem common stock. The amounts represent compensation for services in 2016, even though the Directors received payment in 2016 for their service from May 12, 2016, the day after the 2016 annual meeting, through May 9, 2017, the day prior to the Annual Meeting.
|
(2)
|
The grant date fair value for each RSU was $42.88, which was the closing price of Xylem’s common stock on May 13, 2016. The number of RSUs granted to all non-employee Directors was determined by dividing the annual equity award by the closing price of Xylem’s common stock on the date of grant. Directors receive dividend equivalents on the RSUs but have no other rights as shareholders with respect to the RSUs until vesting.
|
Name
|
Outstanding
Stock Awards
|
Outstanding
Option Awards
|
Curtis J. Crawford
|
2,799
|
2,860
|
Robert F. Friel
|
2,799
|
—
|
Victoria D. Harker
|
2,799
|
—
|
Sten E. Jakobsson
|
2,799
|
—
|
Steven R. Loranger
|
2,799
|
181,379
|
Edward J. Ludwig
|
2,799
|
—
|
Surya N. Mohapatra
|
2,799
|
2,860
|
Jerome A. Peribere
|
2,799
|
—
|
Markos I. Tambakeras
|
4,373
|
2,860
|
25
|
Xylem
2017 Proxy Statement
|
C
OMPENSATION
D
ISCUSSION AND
A
NALYSIS
|
NEO
|
Position
|
Patrick K. Decker
|
President & Chief Executive Officer (“CEO”)
|
E. Mark Rajkowski
|
Senior Vice President ("SVP") and Chief Financial Officer (“CFO”)
|
Kenneth Napolitano
|
SVP and President, Applied Water Systems
|
Colin R. Sabol
|
SVP and President, Analytics and Treatment
|
Claudia S. Toussaint
|
SVP, General Counsel and Corporate Secretary
|
Shashank Patel
|
Former Interim CFO
|
Key Financial Results for 2016
l
Revenue
was $3.8 billion, up 3% on a reported basis and 1% organically from 2015
l
Net Income
was $260 million and
Earnings Per Share
of $1.45, with an
Operating Margin
of 10.8%
l
Adjusted Net Income*
was $364 million and
Adjusted Earnings Per Share*
of $2.03, up 10% from 2015
l
Adjusted Operating Margin*
was 13.6%, up 70 basis points from 2015
|
•
|
Enhance Commercial Leadership:
Our focus on excellence in customer experience is increasing sales opportunities and generating more revenue. Our sales training provides best practice tools and processes, which help our salespeople partner with customers on long-term business solutions, rather than sales transactions. As a result, we continue to secure significant wins that demonstrate our ability to understand customers’ needs and offer compelling solutions.
|
•
|
Grow Emerging Markets:
We are executing our growth plan, including expanding our presence and capabilities in key markets and investing in product localization to be more competitive in the marketplace. While performance for the full year was mixed across the emerging markets region, we began to build momentum in the fourth quarter and expect to continue that momentum into 2017.
|
Xylem
2017 Proxy Statement
|
26
|
•
|
Strengthen Innovation and Technology:
We are steadily advancing our R&D and innovation agenda and have increased our vitality index (which measures new products sales). We are investing across the priority areas we have identified and improving our global capabilities.
|
•
|
Build a Continuous Improvement Culture:
We continue to improve our operating efficiency and manage costs sustainably. This will enhance our customers’ experience while generating savings that can be reinvested for growth. We delivered cost reductions of nearly $145 million through our global procurement organization, improved productivity, and lean initiatives.
|
•
|
Cultivate Leadership and Talent Development:
Our ongoing investments in talent development are a critical enabler to Xylem’s sustainable success. In 2016 we made great strides in strengthening our learning and development offerings across the organization. These efforts help build our leadership breadth and depth, and foster a work environment that enables every colleague to do their best.
|
27
|
Xylem
2017 Proxy Statement
|
•
|
Base Salary:
The LDCC made adjustments ranging from 2% to 5% to the NEOs’ base salaries based on its review of market competitive levels (described in detail under “Our Executive Compensation Program - Base Salary”).
|
2016 Performance Year
|
|||||||
|
|
|
|
|
|
|
|
|
Team
|
{
|
25%
|
Revenue
|
|
|
|
|
|
|
|
|
|
||
|
25%
|
Operating Income
|
+
Individual
|
25%
|
|
||
|
|
|
|
|
|
||
|
25%
|
Working Capital (as a percentage of Revenue)
|
|
|
|
||
|
|
|
|
|
|
|
|
•
|
Long-Term Incentive Compensation:
Our Long-Term Incentive Plan (“LTIP”) awards are designed to align executive pay with long-term value creation for shareholders. Since the introduction of performance share units (“PSUs”) in 2013, our mix of LTIP awards has been 33% PSUs based on a pre-set, three-year return on invested capital (“ROIC”) metric, 33% time-based restricted stock units (“RSUs”), and 34% stock options. Starting in 2016, to further align with shareholder interests and to balance both internal and external performance goals, the LDCC increased the mix of PSUs to 50% and added a relative total shareholder return (“TSR”) metric to the PSUs. The 2016 LTIP awards for NEOs included the following (described in detail under “Our Executive Compensation Program - Long-Term Incentive Plan”):
|
2016 Performance Year
|
|||
|
|
|
|
|
25%
|
PSUs to be earned based on a pre-set, 3-year ROIC metric
|
|
|
|
|
|
|
25%
|
PSUs to be earned based on a 3-year TSR metric relative to S&P 500 (excluding financial services)
|
|
|
|
|
|
|
25%
|
Time-based RSUs
|
|
|
|
|
|
|
25%
|
Stock Options
|
|
|
|
|
|
Xylem
2017 Proxy Statement
|
28
|
What We Do
|
|
What We Don’t Do
|
||
ü
|
Pay-for-Performance:
A significant portion of our NEO pay is performance-based, variable pay and not fixed pay.
|
|
û
|
No Perquisites:
We currently do not provide any perquisites for our NEOs.
|
ü
|
Balanced Compensation Design:
Our executive compensation program is designed to align with the Company’s business strategy and shareholders’ interests in the context of market practices.
|
|
û
|
No Special Retirement Plan for NEOs:
We do not provide any retirement benefits to NEOs, other than the benefits available to the broader population of salaried employees.
|
ü
|
Peer Group Selection:
We conduct a robust annual review and validation of our compensation peer group to ensure that the number of peer companies is appropriate and each peer company remains comparable.
|
|
û
|
No Fixed-Term Employment Contracts:
We do not have a fixed-term employment contract with any of our NEOs. We entered into a letter agreement with Mr. Decker, as disclosed in our 2014 Proxy Statement, which does not provide for a specific term of employment.
|
ü
|
Compensation Benchmarking:
We conduct benchmarking exercises on a regular basis to ensure that our compensation programs are competitive and have a balanced portfolio approach for fixed versus variable compensation.
|
|
û
|
No Tax Gross-Ups:
Tax gross-ups are not provided by Xylem except in the case of taxable relocation expenses or non-permanent international assignment support. We do not provide Section 280G excise tax gross-ups under our plans.
|
ü
|
Proactive Management of Share Utilization:
Throughout the year, we regularly review and project share utilization to ensure reasonable overhang and annual run rate levels.
|
|
û
|
Prohibition on Speculative Transactions:
We have an anti-shorting, pledging and hedging policy which prohibits our officers and Directors from pledging Xylem securities or purchasing financial instruments, or otherwise engaging in transactions that are designed to or have the effect of hedging or offsetting any decrease in the market value of Xylem securities.
|
ü
|
Annual Risk Assessment:
Annually, we conduct a global risk assessment of incentive-based compensation to identify any issues that could have a material, adverse impact on the Company. No material adverse risks were identified in the annual compensation risk assessment.
|
|
||
ü
|
Clawback Policy:
We have a clawback policy which applies to both cash and equity performance-based compensation.
|
|
|
|
ü
|
Double-Trigger Change of Control Provision:
We have adopted double-trigger vesting upon a change of control for our severance plans and LTIP awards.
|
|
|
|
ü
|
Stock Ownership Guidelines:
All of our NEOs are expected to hold stock valued at a multiple of base salary.
|
|
|
|
ü
|
Insider-Trading Policy:
We have a robust insider-trading policy.
|
|
|
|
ü
|
Engagement of an Independent Compensation Consultant:
The LDCC engages an independent compensation consultant to provide advice on executive officer and Director compensation matters.
|
|
|
|
O
UR
E
XECUTIVE
C
OMPENSATION
P
ROGRAM
|
•
|
Design of compensation programs should reward executives for long-term growth and profitability and should be reasonable, fair, fully disclosed, and strongly aligned with long-term shareholder value creation.
|
•
|
Compensation should be simple, flexible and sustainable to support Xylem’s on-going business transformation and should be reviewed annually to ensure continued support of the Company’s business objectives.
|
•
|
Target compensation (base salary, target annual incentive compensation and target long-term incentive compensation) opportunities should reflect the market median for median performance and may be adjusted for an individual’s performance, strategic impact, level of responsibility and tenure in the position. Actual compensation and incentive award payouts should vary with annual and long-term performance.
|
•
|
Compensation should be designed and structured so that unnecessary or excessive risk-taking behavior is discouraged.
|
29
|
Xylem
2017 Proxy Statement
|
Xylem
2017 Proxy Statement
|
30
|
Compensation Element
|
Key Role
|
Purpose
|
|
Base Salary
|
l
|
Fixed component of compensation.
|
Designed to be competitive with our peers, allowing us to attract and retain the best talent.
|
Annual
Incentive Plan
|
l
|
Variable component of compensation.
|
Designed to link pay to Xylem’s annual performance and strategic growth objectives, as well as individual results.
|
l
|
A cash incentive plan intended to recognize results in a single performance year.
|
||
Long-Term
Incentive Plan
|
l
|
Variable component of compensation.
|
Designed to link pay to long-term financial performance, to align executive incentives with shareholder value, and to help facilitate stock ownership and share retention.
|
l
|
50% of the LTIP award is provided as PSUs based on three-year absolute ROIC metric (25%) and three-year relative TSR metric (25%).
|
||
l
|
The other 50% of the LTIP award is provided as time-based RSUs (25%) and stock options (25%).
|
||
l
|
The amount of the LTIP award is based on a number of factors including strategic impact of the role, performance and competitiveness with market median.
|
•
|
Contributions to the success of the Company.
|
•
|
The individual’s level and consistency of performance.
|
•
|
Proficiency in the position, skill set and knowledge for the position.
|
•
|
Tenure in the position.
|
•
|
Specific recruitment circumstances for newly-hired executives.
|
Name
|
2015
Base Salary
($)
|
2016
Base Salary
($)
|
%
Increase
|
Patrick K. Decker
|
950,000
|
980,000
|
3.2%
|
Kenneth Napolitano
|
410,000
|
418,200
|
2.0%
|
Colin R. Sabol
|
410,000
|
422,300
|
3.0%
|
Claudia S. Toussaint
|
410,000
|
430,500
|
5.0%
|
31
|
Xylem
2017 Proxy Statement
|
|
|
Actual Performance vs. Target for Payout Levels
|
|||
Metric
|
Weighting
|
Below
Threshold
(0% of Target)
|
Threshold
Payout
(50% of Target)
|
Target
Payout
(100% of Target)
|
Maximum
Payout
(200% of Target)
|
Revenue (1)
|
25%
|
<95% of Target
|
95% of Target
|
100% of Target
|
104% of Target
|
Operating Income (2)
|
25%
|
<90% of Target
|
90% of Target
|
100% of Target
|
106.7% of Target
|
Working Capital
(as a % of Revenue) (3)
|
25%
|
>+1% vs. Target
|
+1% vs. Target
|
100% of Target
|
-0.667%% vs. Target
|
(1)
|
Reported GAAP Revenue (excluding the impact of foreign currency fluctuations, unbudgeted acquisitions and divestitures).
|
(2)
|
Reported GAAP Operating Income (excluding the impact of restructuring and realignment costs, Sensus acquisition related costs, special charges, and unbudgeted acquisitions).
|
(3)
|
(Accounts Receivable + Inventory - Accounts Payable - Customer Advances)/Revenue (excluding the impact of currency fluctuation and unbudgeted acquisitions and diverstitures).
|
Xylem
2017 Proxy Statement
|
32
|
Strategic Priorities
|
Core Imperatives
|
•
Enhance Commercial Leadership: generate above-market growth and be a market leader by helping our sales teams sell more and perform better.
•
Grow in Emerging Markets: grow twice as fast as the rest of the market in key emerging market regions by expanding our capabilities and presence.
•
Strengthen our Innovation and Technology: increase investment in R&D and innovation to develop new technologies by focusing on smart technologies, systems intelligence, and advanced treatment and industrial services.
•
Build a “Continuous Improvement” Culture: simplify our business, enhance productivity through tools like Lean Six Sigma, and sharpen our global procurement capabilities.
•
Cultivate Leadership and Talent Development: develop our talent at every level by solidifying our foundation and building more leadership depth and breadth.
|
•
Drive a Culture of Safety and Health: commitment to providing a safe and healthy workplace for employees and protecting our environment.
•
Drive a Culture of Compliance: focus on fostering a culture of compliance, where each Xylem employee takes personal responsibility for acting ethically and with integrity, and promoting an environment where everyone feels empowered to do the right thing.
|
2016 AIP Awards Paid in 2017
|
Team Performance Metrics
|
Weighting
|
2016 Target
Performance
|
2016 Actual
Performance
|
Actual vs.
Target
|
Actual
Payout %
|
Revenue ($MM)
|
25%
|
3,687
|
3,591
|
97.4%
|
74%
|
Operating Income ($MM)
|
25%
|
518
|
510
|
98.5%
|
92%
|
Working Capital (as a % of Revenue)
|
25%
|
21.5%
|
21.8%
|
+0.3%
|
85%
|
|
|
|
Team Performance Score:
|
84%
|
•
|
Attain or exceed 2016 internal stretch targets for revenue, operating income, and working capital;
|
•
|
Champion change to a growth culture to achieve market growth;
|
•
|
Drive business simplification and continuous improvement efforts to expand profit margins;
|
•
|
Accelerate leadership and talent development efforts;
|
•
|
Further improve safety focus and compliance culture; and
|
•
|
Execute accelerated capital deployment while continuing to build robust merger and acquisition pipeline.
|
33
|
Xylem
2017 Proxy Statement
|
Name
|
Base
Salary
($)
|
Target
AIP Award
(% of Salary)
|
Target
Annual
Incentive
($)
|
Range of Potential
Payouts Based on
Team & Individual
Results ($)
|
Total Team
& Individual
Performance
Score (%)
|
Actual
AIP
Payout
($)
|
Patrick K. Decker
|
980,000
|
120%
|
1,176,000
|
0 - 2,352,000
|
85.5%
|
1,005,480
|
E. Mark Rajkowski*
|
600,000
|
80%
|
360,000
|
0 - 720,000
|
91.8%
|
330,300
|
Kenneth Napolitano
|
418,200
|
70%
|
292,740
|
0 - 585,480
|
85.5%
|
250,290
|
Colin R. Sabol
|
422,300
|
70%
|
295,610
|
0 - 591,220
|
85.5%
|
252,750
|
Claudia S. Toussaint
|
430,500
|
65%
|
279,825
|
0 - 559,650
|
90.5%
|
253,240
|
Shashank Patel**
|
320,000
|
58%
|
184,000
|
0 - 368,000
|
85.5%
|
157,320
|
Components
|
% of
Award
|
Vesting Period
|
Rationale
|
PSUs
|
50%
|
Performance-based vesting that cliff vests at the end of three years.
|
Two balanced performance criteria (ROIC and TSR) provides strong pay-for-performance linkage. Cliff vesting supports long-term alignment with shareholder value and retention of the Company’s NEOs.
|
RSUs
|
25%
|
Time-based vesting in three annual installments.
|
Three-year vesting supports long-term alignment with shareholder value in conjunction with our stock ownership guidelines and retention of the Company’s NEOs.
|
Stock Options
|
25%
|
Time-based vesting in three annual installments.
|
Actual value materializes only if the share price appreciates over the stock options’ exercise price before the stock options expire. Supports share price performance and long-term alignment with shareholder value creation over the life of the option.
|
•
|
50% of the PSUs were granted at target (100%) with actual payout (0%-175% of target) contingent upon the achievement of a pre-set, three-year ROIC performance target. We believe ROIC is aligned with our efforts to build long-term value for shareholders by focusing on the effective allocation of capital. The ROIC
|
Xylem
2017 Proxy Statement
|
34
|
Performance Level
|
2016-2018 ROIC*
|
Payout as a % of Target
|
Maximum
|
11.6%
|
175%
|
Target
|
11.3%
|
100%
|
Minimum
|
10.5%
|
0%
|
•
|
50% of the PSUs were granted at target (100%) with actual payout (0%-175% of target) based on three-year Xylem TSR relative to companies in the S&P 500 Index (excluding Financial Services Companies). We believe TSR helps us to further align with shareholder interests and along with ROIC, provides a balanced approach to address both internal and external performance. The potential payout levels (as a percentage of target) based on actual performance are summarized below (results are interpolated between threshold - target and target - maximum):
|
Performance Level
|
2016-2018 Relative TSR Rank
|
Payout as a % of Target
|
Maximum
|
75
th
Percentile and Above
|
175%
|
Target
|
50
th
Percentile
|
100%
|
Threshold
|
25
th
Percentile
|
25%
|
Below Threshold
|
Below 25
th
Percentile
|
0%
|
•
|
Earned PSUs will be settled in shares upon vesting.
|
•
|
Holders of PSUs do not have voting rights and do not receive cash dividends during the restriction period.
|
•
|
Dividend equivalents are accrued and paid in cash only if and when PSUs vest.
|
•
|
If an employee resigns or is terminated prior to vesting, the PSUs are forfeited entirely.
|
•
|
If an employee retires, dies or becomes disabled, a prorated portion of the PSUs vests.
|
•
|
PSUs will vest in full (assuming target performance) upon termination of employment by the Company without cause or by the employee for good reason within two years of a change of control or if the buyer does not assume or replace the awards in connection with a change of control.
|
Status of Annual PSU Award for Most Recently Completed Performance Cycle
|
Performance Cycle
|
Performance Metric*
|
Performance Level
|
Payout
|
Status
|
2014-2016
|
ROIC with
TSR as modifier
|
Maximum: 12.1%
Target: 11.7%
Threshold: 11.3%
|
200%
100%
50%
|
No shares were earned from this award due to below threshold performance (10.9%)
|
•
|
RSUs awarded as part of the annual LTIP award vest in three equal annual installments.
|
•
|
RSUs will be settled in shares upon vesting.
|
•
|
Holders of RSUs do not have voting rights and do not receive cash dividends until the RSUs are settled.
|
35
|
Xylem
2017 Proxy Statement
|
•
|
Dividend equivalents are accrued and paid in cash only upon vesting.
|
•
|
If an employee resigns or is terminated prior to vesting, the RSUs are forfeited entirely.
|
•
|
If an employee retires, a prorated portion of the RSUs vest and applicable dividends will be paid.
|
•
|
If an employee dies or becomes disabled, the RSUs vest in full.
|
•
|
RSUs will vest in full upon termination of employment by the Company without cause or by the employee for good reason within two years of a change of control or if the buyer does not assume or replace the awards in connection with a change of control.
|
•
|
Stock options vest in three equal annual installments and cannot be exercised prior to vesting.
|
•
|
If an employee resigns or is terminated prior to vesting, the unvested portions of the stock options are forfeited entirely. The vested portions of the stock options expire the earlier of three months following the termination date or the original expiration date.
|
•
|
If an employee retires, a pro-rated portion of the unvested portions of the stock options vest and remain exercisable until the earlier of three years following the retirement date or the original expiration date.
|
•
|
If an employee dies or becomes disabled, the unvested portions of the stock options vest in full and remain exercisable until the earlier of three years following the death or disability date or the original expiration date.
|
•
|
The unvested portion of the stock options will vest in full upon termination of employment by the Company without cause or by the employee for good reason within two years of a change of control or if the buyer does not assume or replace the awards in connection with a change of control.
|
•
|
Retirement plans generally include the tax-qualified retirement savings plan, the non-qualified retirement savings plan, and the deferred compensation plans. We do not provide defined benefit retirement plans.
|
•
|
Benefit plans generally include group medical and dental coverage, group life insurance, group accidental death and dismemberment insurance, and short- and long-term disability insurance.
|
Xylem
2017 Proxy Statement
|
36
|
37
|
Xylem
2017 Proxy Statement
|
Xylem
2017 Proxy Statement
|
38
|
Name and
Principal Position (1)
|
Year
|
Salary
($)(2)
|
Bonus
($)(3)
|
Stock
Awards
($)(4)
|
Option
Awards
($)(5)
|
Non-Equity
Incentive
Plan
Compensation
($)(6)
|
All Other
Compensation
($)(7)
|
Total
($)
|
Patrick K. Decker
|
2016
|
975,384
|
—
|
4,012,540
|
1,250,001
|
1,005,480
|
138,660
|
7,382,065
|
President and
|
2015
|
981,731
|
—
|
3,299,978
|
1,700,003
|
843,960
|
127,798
|
6,953,470
|
Chief Executive Officer
|
2014
|
711,538
|
—
|
4,626,428
|
1,506,814
|
1,004,180
|
378,909
|
8,227,869
|
E. Mark Rajkowski
|
2016
|
461,538
|
—
|
1,430,075
|
374,999
|
330,300
|
55,429
|
2,652,341
|
SVP and Chief Financial Officer
|
|
|
|
|
|
|
|
|
Kenneth Napolitano
|
2016
|
416,938
|
—
|
642,055
|
200,000
|
250,290
|
46,706
|
1,555,989
|
SVP and President,
|
2015
|
423,846
|
—
|
462,014
|
238,004
|
218,120
|
77,036
|
1,419,020
|
Applied Water Systems
|
2014
|
400,000
|
—
|
462,020
|
238,002
|
264,320
|
80,625
|
1,444,967
|
Colin R. Sabol
|
2016
|
420,408
|
—
|
601,881
|
187,499
|
252,750
|
87,715
|
1,550,253
|
SVP and President,
|
2015
|
415,962
|
—
|
529,967
|
170,003
|
203,190
|
88,677
|
1,407,799
|
Analytics and Treatment
|
2014
|
400,000
|
—
|
330,002
|
170,000
|
226,560
|
84,573
|
1,211,135
|
Claudia S. Toussaint
|
2016
|
427,346
|
—
|
521,654
|
162,504
|
253,240
|
47,641
|
1,412,385
|
SVP, General Counsel and
|
2015
|
425,769
|
—
|
362,880
|
187,003
|
209,200
|
44,448
|
1,229,300
|
Corporate Secretary
|
2014
|
59,923
|
300,000
|
2,250,016
|
—
|
41,930
|
7,153
|
2,659,022
|
Shashank Patel
|
2016
|
382,034
|
75,000
|
200,627
|
62,500
|
157,320
|
60,887
|
938,368
|
Former Interim Chief Financial Officer
|
2015
|
428,307
|
—
|
272,494
|
72,496
|
125,110
|
55,025
|
953,432
|
(1)
|
Mr. Rajkowski joined the Company in March of 2016. Mr. Patel became an NEO in 2015 as a result of his appointment as Interim CFO effective July 30, 2015 and stepped into his new role in March of 2016.
|
(2)
|
Amounts in the “Salary” column represent the actual base salary earned by the NEOs in 2016 and are pro-rated based on the NEO’s start date. Mr. Patel’s amount also includes a special allowance of $69,228 (approximately $25,000 per month) to recognize additional responsibilities related to the Interim CFO assignment. 2015 includes one additional pay period.
|
(3)
|
The amount for Mr. Patel represents a one-time payment in recognition of the successful completion of the Interim CFO assignment and significant contributions in the Sensus acquisition deal. The 2014 amount for Ms. Toussaint represents a one-time payment in recognition of cash incentives, perquisites, and the portion of near-term equity awards forfeited in connection with her acceptance of the Company’s offer of employment.
|
(4)
|
Amounts in the “Stock Awards” column represent the aggregate grant date fair value computed in accordance with FASB ASC Topic 718 for the PSU and RSU awards. Assuming the maximum performance is achieved for the 2016 PSU award, the maximum grant date fair value of the PSU award is $5,293,898 for Mr. Decker; $1,680,122 for Mr. Rajkowski; $847,087 for Mr. Napolitano; $794,085 for Mr. Sabol; $688,239 for Ms. Toussaint; and $264,695 for Mr. Patel. A discussion of the awards and assumptions used in calculating the 2016 values may be found in Note 16 to the Consolidated and Combined Financial Statements in the Company’s 2016 Annual Report on Form 10-K filed on February 23, 2017.
|
(5)
|
Amounts in the “Option Awards” column represent the aggregate grant date fair value computed in accordance with FASB ASC Topic 718 for the stock option awards. A discussion of assumptions relating to 2016 stock option awards may be found in Note 16 to the Consolidated and Combined Financial Statements in the Company’s 2016 Annual Report on Form 10-K filed on February 23, 2017.
|
(6)
|
Amounts in the “Non-Equity Incentive Plan Compensation” column represent AIP awards earned for the each performance year.
|
(7)
|
Amounts in this column represent items specified in the “All Other Compensation Table” below.
|
Name
|
Company
Contribution
to Tax-Qualified
Retirement
Savings Plan
($)(a)
|
Company
Contribution
to Non-Qualified
Retirement
Savings Plan
($)(b)
|
Company
Contribution
to Deferred
Compensation
Plan
($)(c)
|
Other
($)(d)
|
Total All
Other
Compensation
($)
|
Patrick K. Decker
|
18,550
|
120,110
|
0
|
—
|
138,660
|
E. Mark Rajkowski
|
18,550
|
36,879
|
—
|
—
|
55,429
|
Kenneth Napolitano
|
18,550
|
14,140
|
14,016
|
—
|
46,706
|
Colin R. Sabol
|
18,550
|
28,571
|
—
|
40,594
|
87,715
|
Claudia S. Toussaint
|
18,550
|
15,091
|
14,000
|
—
|
47,641
|
Shanshank Patel
|
31,800
|
24,615
|
0
|
4,472
|
60,887
|
(a)
|
These amounts include contributions in fiscal year 2016 as well as contributions for the 2016 AIP award earned in 2016 and paid in 2017.
|
(b)
|
These amounts include contributions in fiscal year 2016 as well as contributions for the 2016 AIP award earned in 2016 and paid in 2017. Xylem contributions are unfunded and participants have access to the same investment funds available to participants in the tax-qualified retirement savings plan.
|
(c)
|
These amounts include contributions for the 2016 AIP award earned in 2016 and paid in 2017 to the participants under the Xylem Deferred Compensation Plan.
|
(d)
|
For Mr. Sabol the amount represents partial relocation benefits he received in connection with his new assignment started at the end of 2015. This is consistent with benefits provided to other employees that require relocation due to a new work assignment.
|
39
|
Xylem
2017 Proxy Statement
|
|
|
Estimated Future Payouts
Under Non-Equity Incentive
Plan Awards(1)
|
|
Estimated Future Payouts
Under Equity Incentive
Plan Awards (2)
|
All Other
Stock
Awards:
Number
of Shares
of Stock
or Units
(#)(3)
|
All Other
Option
Awards:
Number of
Securities
Underlying
Options
(#)(4)
|
Exercise
or Base
Price of
Option
Awards
($/Sh)(5)
|
Grant
Date
Fair
Value
of Stock
and
Option
Awards
($)(6)
|
||||
Name
|
Grant
Date
|
Threshold
($)
|
Target
($)
|
Maximum
($)
|
|
Threshold
(#)
|
Target
(#)
|
Maximum
(#)
|
||||
Patrick K. Decker
|
|
0
|
1,176,000
|
2,352,000
|
|
|
|
|
|
|
|
—
|
|
2/24/16
|
|
|
|
|
0
|
66,720
|
116,760
|
|
|
|
2,762,541
|
|
2/24/16
|
|
|
|
|
|
|
|
33,360
|
|
|
1,249,999
|
|
2/24/16
|
|
|
|
|
|
|
|
|
138,581
|
37.47
|
1,250,001
|
E. Mark Rajkowski
|
|
0
|
480,000
|
960,000
|
|
|
|
|
|
|
|
—
|
|
5/5/16
|
|
|
|
|
0
|
18,060
|
31,605
|
|
|
|
855,051
|
|
5/5/16
|
|
|
|
|
|
|
|
9,030
|
|
|
375,016
|
|
5/5/16
|
|
|
|
|
|
|
|
4,816
|
|
|
200,008
|
|
5/5/16
|
|
|
|
|
|
|
|
|
40,453
|
41.53
|
374,999
|
Ken Napolitano
|
|
0
|
292,740
|
585,480
|
|
|
|
|
|
|
|
—
|
|
2/24/16
|
|
|
|
|
0
|
10,676
|
18,683
|
|
|
|
442,040
|
|
2/24/16
|
|
|
|
|
|
|
|
5,338
|
|
|
200,015
|
|
2/24/16
|
|
|
|
|
|
|
|
|
22,173
|
37.47
|
200,000
|
Colin R. Sabol
|
|
0
|
295,610
|
591,220
|
|
|
|
|
|
|
|
—
|
|
2/24/16
|
|
|
|
|
0
|
10,008
|
17,514
|
|
|
|
414,381
|
|
2/24/16
|
|
|
|
|
|
|
|
5,004
|
|
|
187,500
|
|
2/24/16
|
|
|
|
|
|
|
|
|
20,787
|
37.47
|
187,499
|
Claudia S. Toussaint
|
|
0
|
279,825
|
559,650
|
|
|
|
|
|
|
|
—
|
|
2/24/16
|
|
|
|
|
0
|
8,674
|
15,180
|
|
|
|
359,147
|
|
2/24/16
|
|
|
|
|
|
|
|
4,337
|
|
|
162,507
|
|
2/24/16
|
|
|
|
|
|
|
|
|
18,016
|
37.47
|
162,504
|
Shashank Patel
|
|
0
|
184,000
|
368,000
|
|
|
|
|
|
|
|
—
|
|
2/24/16
|
|
|
|
|
0
|
3,336
|
5,838
|
|
|
|
138,127
|
|
2/24/16
|
|
|
|
|
|
|
|
1,668
|
|
|
62,500
|
|
2/24/16
|
|
|
|
|
|
|
|
|
6,929
|
37.47
|
62,500
|
(1)
|
Amounts reflect the annualized minimum, target and maximum payment levels, respectively, if an award payout is achieved under the 2016 AIP described under “Compensation Discussion and Analysis - Annual Incentive Plan.” These potential payments are based on achievement of specific performance metrics and are completely at risk.
|
(2)
|
Amounts reflect the number of PSUs granted in 2016, which were determined using the closing price of Xylem stock on the respective grant dates. The 2016 annual awards vest in full at the end of the three-year restriction period following the grant date for normal annual grants - February 24, 2016 (“Annual Grant Date”), to the extent that they are earned based on pre-set ROIC and relative TSR performance goals and provided that the executive remains an employee as of the vesting date as described in “Compensation Discussion and Analysis - Elements of Our Compensation Program”.
|
(3)
|
Amounts reflect the number of RSUs granted in 2016, which were determined using the closing price of Xylem stock on the respective grant dates. The 2016 annual awards vest in three equal installments on each of the first, second, and third anniversaries of the Annual Grant Date provided that the executive remains an employee as of the vesting date.
|
(4)
|
Amounts reflect the number of stock options granted in 2016, which was determined using the binomial lattice value on the respective grant dates. These awards vest in three equal installments on each of the first, second, and third anniversaries of the Annual Grant Date provided that the executive remains an employee as of each vesting date. The options expire ten years after the Annual Grant Date.
|
(5)
|
The stock option exercise price equals the closing price of Xylem stock on the respective grant dates.
|
(6)
|
Amounts in this column represent the grant date fair value computed in accordance with FASB ASC Topic 718 for PSU, RSU and stock option awards granted to the NEOs in 2016.
|
Xylem
2017 Proxy Statement
|
40
|
|
Option Awards
|
|
RSU Awards
|
|
PSU Awards
|
||||||
Name
|
Grant
Date
|
Number of Securities Underlying Unexercised Options
Exercisable
(#)(1)
|
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
(#)(2)
|
Option
Exercise
Price ($)
|
Option
Expiration
Date
|
|
Number of
Shares or
Units of
Stock that
Have Not
Vested
(#)(3)
|
Market
Value of
Shares or
Units of
Stock that
Have Not
Vested
($)(4)
|
|
Number of
Shares or
Units of
Stock that
Have Not
Vested
(#)(5)
|
Market
Value of
Shares or
Units of
Stock that
Have Not
Vested
($)(4)
|
Patrick K. Decker
|
3/17/14
|
110,390
|
55,194
|
36.8100
|
2/25/24
|
|
142,086
|
7,036,099
|
|
112,604
|
5,576,150
|
|
2/24/15
|
66,433
|
132,864
|
35.9600
|
2/24/25
|
|
|
|
|
|
|
|
2/24/16
|
—
|
138,581
|
37.4700
|
2/24/26
|
|
|
|
|
|
|
E. Mark Rajkowski
|
5/5/16
|
—
|
40,453
|
41.5300
|
2/24/26
|
|
13,846
|
685,654
|
|
18,060
|
894,331
|
Kenneth Napolitano
|
3/5/10
|
17,999
|
—
|
30.0295
|
3/5/20
|
|
17,722
|
877,593
|
|
17,100
|
846,792
|
|
3/3/11
|
17,527
|
—
|
32.3818
|
3/3/21
|
|
|
|
|
|
|
|
11/7/11
|
46,140
|
—
|
24.6000
|
11/7/21
|
|
|
|
|
|
|
|
3/2/12
|
32,662
|
—
|
26.6000
|
3/2/22
|
|
|
|
|
|
|
|
3/1/13
|
30,909
|
—
|
27.4900
|
3/1/23
|
|
|
|
|
|
|
|
2/25/14
|
15,883
|
7,941
|
38.7600
|
2/25/24
|
|
|
|
|
|
|
|
2/24/15
|
9,301
|
18,601
|
35.9600
|
2/24/25
|
|
|
|
|
|
|
|
2/24/16
|
—
|
22,173
|
37.4700
|
2/24/26
|
|
|
|
|
|
|
Colin R. Sabol
|
3/1/13
|
12,078
|
—
|
27.4900
|
3/1/23
|
|
19,306
|
956,033
|
|
14,596
|
722,794
|
|
2/25/14
|
11,345
|
5,672
|
38.7600
|
2/25/24
|
|
|
|
|
|
|
|
2/24/15
|
6,644
|
13,286
|
35.9600
|
2/24/25
|
|
|
|
|
|
|
|
2/24/16
|
|
20,787
|
37.4700
|
2/24/26
|
|
|
|
|
|
|
Claudia S. Toussaint
|
2/24/15
|
7,308
|
14,615
|
35.9600
|
2/24/25
|
|
19,886
|
984,755
|
|
13,721
|
679,464
|
|
2/24/16
|
—
|
18,016
|
37.4700
|
2/24/26
|
|
|
|
|
|
|
Shashank Patel
|
3/3/11
|
4,951
|
—
|
32.3818
|
3/3/21
|
|
10,689
|
529,319
|
|
3,336
|
165,199
|
|
11/7/11
|
2,621
|
—
|
24.6000
|
11/7/21
|
|
|
|
|
|
|
|
3/2/12
|
8,398
|
—
|
26.6000
|
3/2/22
|
|
|
|
|
|
|
|
3/1/13
|
7,555
|
—
|
27.4900
|
3/1/23
|
|
|
|
|
|
|
|
2/25/14
|
4,004
|
2,002
|
38.7600
|
2/25/24
|
|
|
|
|
|
|
|
2/24/15
|
2,833
|
5,666
|
35.9600
|
2/24/25
|
|
|
|
|
|
|
|
2/24/16
|
—
|
6,929
|
37.4700
|
2/24/26
|
|
|
|
|
|
|
(1)
|
All stock option awards vest in three equal installments over the three-year period following the grant date.
|
(2)
|
The following table provides the vesting schedule for unvested stock options (vesting occurs on the applicable anniversary of the Annual Grant Date).
|
|
Grant
|
Vesting Schedule (#)
|
||
Name
|
Date
|
2017
|
2018
|
2019
|
Patrick K. Decker
|
3/17/14
|
55,194
|
—
|
—
|
|
2/24/15
|
66,432
|
66,432
|
—
|
|
2/24/16
|
46,194
|
46,194
|
46,193
|
E. Mark Rajkowski
|
5/5/16
|
13,485
|
13,484
|
13,484
|
Kenneth Napolitano
|
2/25/14
|
7,941
|
—
|
—
|
|
2/24/15
|
9,301
|
9,301
|
—
|
|
2/24/16
|
7,391
|
7,391
|
7,391
|
Colin R. Sabol
|
2/25/14
|
5,672
|
—
|
—
|
|
2/24/15
|
6,643
|
6,643
|
—
|
|
2/24/16
|
6,929
|
6,929
|
6,929
|
Caludia S. Toussaint
|
2/24/15
|
7,308
|
7,307
|
—
|
|
2/24/16
|
6,006
|
6,005
|
6,005
|
Shashank Patel
|
2/25/14
|
2,002
|
0
|
0
|
|
2/24/15
|
2,833
|
2,833
|
0
|
|
2/24/16
|
2,310
|
2,310
|
2,309
|
41
|
Xylem
2017 Proxy Statement
|
(3)
|
Amounts reflect unvested RSUs. The following table provides the vesting schedule (generally occurs on the applicable anniversary of the grant date except for Mr. Decker’s 2014 grant of 40,342 shares, which vests on February 25, 2017, and Mr. Rajkowski’s 2016 grant of 9,030 shares, which vests in three equal installments on the anniversary dates of the February 24, 2016 grant date:
|
|
Grant
|
Vesting Schedule (#)
|
||
Name
|
Date
|
2017
|
2018
|
2019
|
Patrick K. Decker
|
3/17/14
|
22,500
|
—
|
—
|
|
3/17/14
|
40,342
|
—
|
—
|
|
2/24/15
|
—
|
45,884
|
—
|
|
2/24/16
|
11,120
|
11,120
|
11,120
|
E. Mark Rajkowski
|
5/5/16
|
3,010
|
3,010
|
3,010
|
|
5/5/16
|
1,606
|
1,605
|
1,605
|
Kenneth Napolitano
|
2/25/14
|
5,960
|
—
|
—
|
|
2/24/15
|
—
|
6,424
|
—
|
|
2/24/16
|
1,780
|
1,779
|
1,779
|
Colin R. Sabol
|
2/25/14
|
4,257
|
—
|
—
|
|
2/24/15
|
—
|
4,588
|
—
|
|
11/2/15
|
—
|
5,457
|
—
|
|
2/24/16
|
1,668
|
1,668
|
1,668
|
Caludia S. Toussaint
|
10/29/14
|
10,502
|
—
|
—
|
|
2/24/15
|
—
|
5,047
|
—
|
|
2/24/16
|
1,446
|
1,446
|
1,445
|
Shashank Patel
|
2/25/14
|
1,548
|
0
|
0
|
|
2/24/15
|
0
|
2,016
|
0
|
|
11/2/15
|
0
|
5,457
|
0
|
|
2/24/16
|
556
|
556
|
556
|
(4)
|
Market values were determined based on the Company’s closing stock price of $49.52 on December 30, 2016.
|
(5)
|
Amounts reflect the unvested PSUs at target and exclude the 2014 grants where no shares were earned due to below threshold performance. The following table provides the vesting schedule (generally occurs on the applicable anniversary of the grant date except for Mr. Rajkowski’s 2016 grant, which vests on February 24, 2019):
|
|
Grant
|
Vesting Schedule (#)
|
|
Name
|
Date
|
2018
|
2019
|
Patrick K. Decker
|
2/24/15
|
45,884
|
—
|
|
2/24/16
|
—
|
66,720
|
E. Mark Rajkowski
|
5/5/16
|
—
|
18,060
|
Kenneth Napolitano
|
2/24/15
|
6,424
|
—
|
|
2/24/16
|
—
|
10,676
|
Colin R. Sabol
|
2/24/15
|
4,588
|
—
|
|
2/24/16
|
—
|
10,008
|
Caludia S. Toussaint
|
2/24/15
|
5,047
|
0
|
|
2/24/16
|
0
|
8,674
|
Shashank Patel
|
2/24/16
|
0
|
3,336
|
Name
|
Option Awards
|
|
Stock Awards
|
||
Number of Shares
Acquired on
Exercise (#)
|
Value Realized
on Exercise($)(1)
|
|
Number of Shares
Acquired on
Vesting (#)
|
Value Realized
on Vesting($)(2)
|
|
Patrick K. Decker
|
—
|
—
|
|
22,500
|
877,725
|
E. Mark Rajkowski
|
—
|
—
|
|
—
|
—
|
Kenneth Napolitano
|
—
|
—
|
|
8,403
|
318,810
|
Colin R. Sabol
|
66,738
|
1,164,990
|
|
6,002
|
227,716
|
Claudia S. Toussaint
|
—
|
—
|
|
42,005
|
2,030,102
|
Shashank Patel
|
—
|
—
|
|
2,001
|
75,918
|
(1)
|
This amount reflects number of shares acquired upon exercise of stock options multiplied by the difference between the Xylem stock price on the date of exercise and the exercise price of stock options.
|
(2)
|
These amounts reflect the value realized upon the vesting of RSUs based upon the closing price of Xylem stock on the date of vesting.
|
Xylem
2017 Proxy Statement
|
42
|
Name
|
Plan Name
|
Executive
Contributions
in Last
Fiscal Year
($)(1)
|
Registrant
Contributions
in Last
Fiscal Year
($)(2)
|
Aggregate
Earnings
in Last
Fiscal Year
($)(3)
|
Aggregate
Withdrawals/
Distributions
($)
|
Aggregate
Balance
at Last
Fiscal Year End
($)(4)
|
Patrick K. Decker
|
Deferred Compensation
|
—
|
—
|
—
|
—
|
—
|
|
Non-Qualified Savings
|
—
|
120,110
|
3,595
|
—
|
258,905
|
|
Total
|
—
|
120,110
|
3,595
|
—
|
258,905
|
E. Mark Rajkowski
|
Deferred Compensation
|
—
|
—
|
—
|
—
|
—
|
|
Non-Qualified Savings
|
—
|
36,879
|
116
|
—
|
12,258
|
|
Total
|
—
|
36,879
|
116
|
—
|
12,258
|
Kenneth Napolitano
|
Deferred Compensation
|
200,232
|
14,016
|
—
|
—
|
—
|
|
Non-Qualified Savings
|
—
|
14,140
|
2,200
|
—
|
157,379
|
|
Total
|
200,232
|
28,156
|
2,200
|
—
|
157,379
|
Colin R. Sabol
|
Deferred Compensation
|
—
|
—
|
—
|
—
|
—
|
|
Non-Qualified Savings
|
—
|
28,571
|
8,505
|
—
|
177,565
|
|
Total
|
—
|
28,571
|
8,505
|
—
|
177,565
|
Claudia S. Toussaint
|
Deferred Compensation
|
200,000
|
14,000
|
—
|
—
|
—
|
|
Non-Qualified Savings
|
—
|
15,091
|
2,559
|
—
|
41,643
|
|
Total
|
200,000
|
29,091
|
2,559
|
—
|
41,643
|
Shashank Patel
|
Deferred Compensation
|
—
|
—
|
—
|
—
|
—
|
|
Non-Qualified Savings
|
—
|
24,615
|
704
|
—
|
52,168
|
|
Total
|
—
|
24,615
|
704
|
—
|
52,168
|
(1)
|
Amounts represent the deferred portion of the 2016 AIP, which was credited to NEOs’ account in 2017 and is included in the “Non-Equity Incentive Plan Compensation” column of the “Summary Compensation Table.”
|
(2)
|
Amounts consist of the contributions to the participants under the Xylem Deferred Compensation Plan and SRSP for the 2016 AIP, which were credited to the NEOs’ accounts in 2017. These amounts are reflected in the Non-Qualified Retirement Savings Plan and Deferred Compensation Plan contribution columns in the “All Other Compensation Table” and are included in the “Summary Compensation Table.”
|
(3)
|
The Company does not provide preferential or above-market rates as defined in applicable SEC rules. As a result, the aggregate earnings are not included in the Summary Compensation Table.
|
(4)
|
The amounts represent account balances at 2016 fiscal year end and exclude contributions that were credited in 2017. There were no previously reported amount for Deferred Compensation since 2012. The aggregate balance for SRSP that has been reported as compensation to an NEO in the Summary Compensation Table for previous years since 2012 is $316,701 for Mr. Decker; $36,879 for Mr. Rajkowski; $191,739 for Mr. Napolitano; $123,706 for Mr. Sabol; $43,924 for Ms. Toussaint and $57,805 for Mr. Patel.
|
43
|
Xylem
2017 Proxy Statement
|
Benefit
|
CEO and NEO Hired or Promoted
Prior to May 1, 2012
|
NEO Hired or Promoted on or after
May 1, 2012
(excluding CEO)
|
“Severance Pay” as a multiple of annual base salary and current actual AIP
|
3 Times
|
2 Times
Target AIP for new hire without full-year AIP history
|
Continuation of Health and Life Insurance Benefits at the Same Level
|
3 Years
|
2 Years
|
Other Benefits
|
•
Severance Pay times the current eligible percentage rate of Xylem’s contributions to applicable retirement savings plans; and
•
One year of outplacement services
|
•
|
the aggregate of all severance payments reduced so the present value of payments does not exceed the Safe Harbor Amount as defined by the IRC; or
|
•
|
the aggregate of all severance payments without a reduction.
|
Xylem
2017 Proxy Statement
|
44
|
Name
|
Death/
Disability
($ in millions)(1)
|
Termination
Not For Cause
($ in millions)(2)
|
Change of Control
Termination
Not for Cause/
With Good Reason
($ in millions)(3)
|
Patrick K. Decker
|
11.5
|
4.3
|
20.3
|
E. Mark Rajkowski
|
0.5
|
0.6
|
3.3
|
Kenneth Napolitano
|
1.5
|
0.9
|
4.1
|
Colin R. Sabol
|
1.4
|
0.7
|
4.0
|
Claudia S. Toussaint
|
1.4
|
0.4
|
3.2
|
Shashank Patel
|
0.8
|
—
|
2.0
|
(1)
|
This is a potential lump-sum payment related to the acceleration of unvested equity awards which would have occurred if an NEO had died or become disabled as of December 31, 2016. Equity awards vest according to the terms described in “Compensation Discussion and Analysis - Our Executive Compensation Program - Long-term Incentive Plan”. The amounts shown reflect the market value of RSUs, PSUs (prorated based on actual performance), and in-the-money stock options based on the Company’s December 30, 2016 closing price of $49.52.
|
(2)
|
The amounts shown consist of the following potential payments if an NEO had been terminated not for cause as of December 31, 2016:
|
a.
|
Severance Pay for under the SESPP except for Mr. Decker, who would be paid an amount equal to two times the total of his current annual salary and target AIP based on the severance arrangement included in his letter of agreement filed with our Quarterly Report on Form 10-Q on April 29, 2014. The amounts are paid in the form of periodic payments according to the regular payroll schedule over the severance period.
|
b.
|
The Company’s portion of health and life insurance premium paid monthly for the duration of the severance period under the SESPP.
|
(3)
|
The amounts shown consist of the following potential payments upon termination not for cause or with good reason within two years of change of control:
|
a.
|
Severance Pay under the SSESPP, which is paid in the form of periodic payments according to the regular payroll schedule over the severance period.
|
b.
|
A lump-sum payment for unvested equity awards that would vest according to the terms described in “Compensation Discussion and Analysis — Our Executive Compensation Program — Long-term Incentive Plan.” The amount reflects the market value of RSUs, PSUs (assuming target performance is achieved) and in-the-money stock options based on the Company’s December 30, 2016 closing price of $49.52.
|
c.
|
A lump-sum payment equal to Severance Pay times the then current eligible percentage for the Company’s contribution to the Xylem retirement savings plans as provided under the SSESPP.
|
d.
|
The Company’s portion of health and life insurance premiums under the SSESPP.
|
e.
|
A lump-sum payment equal to the cost of outplacement services for one year following the termination under the SSESPP.
|
45
|
Xylem
2017 Proxy Statement
|
Plan Category
|
Number of Securities
to be Issued Upon
Exercise of
Outstanding Options,
Warrants and Rights
(a)
|
Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights
(b)
|
Number of Securities
Remaining Available
for Future Issuance
Under Equity
Compensation Plans
(excluding securities
reflected in column (a))
(c)
|
Equity Compensation Plans
Approved by Security Holders (1)
|
3,383,314(2)
|
$33.71(3)
|
7,743,940
|
Equity Compensation Plans
Not Approved by Security Holders
|
—
|
—
|
—
|
Total
|
3,383,314
|
$33.71(3)
|
7,743,940
|
(1)
|
Includes the Xylem 2011 Omnibus Incentive Plan and ITT 2003 Equity Incentive Plan.
|
(2)
|
The amount includes 2,126,529 shares of stock options, 899,031 shares underlying restricted stock and RSUs, and 357,754 shares underlying PSUs at target.
|
(3)
|
Represents weighted average exercise price of outstanding stock options only.
|
•
|
If you are a registered owner, you can vote either in person at the Annual Meeting or by proxy.
|
•
|
If you are a beneficial owner, you can vote by submitting voting instructions to your bank, broker, trustee or other nominee. If you are a beneficial owner and would like to vote in person at the Annual Meeting, you will need to obtain a written proxy, executed in your favor, from the shareholder of record (your bank or broker).
|
•
|
If your shares are held through one of Xylem’s savings plans, you can vote by submitting voting instructions to your plan trustee. Your shares cannot be voted in person at the Annual Meeting.
|
By Internet
|
By Telephone
|
By Mail
|
www.proxyvote.com
|
1-800-690-6903
(United States and Canada only)
|
Mark, date and sign your proxy card or voting instruction form and return it in envelope provided
|
Xylem
2017 Proxy Statement
|
46
|
Proposal
|
Vote Required
|
Broker Discretionary
Voting Allowed
|
Board
Recommendation
|
Election of six members of the Xylem Inc. Board of Directors
|
Majority of votes cast. Votes cast “for” a director must exceed the votes cast “against” that director
|
No
|
FOR
|
Ratification of the appointment of Deloitte & Touche LLP for 2017
|
Votes cast “for” the proposal must exceed votes cast “against” the proposal
|
Yes
|
FOR
|
Advisory approval of named executive officer compensation
|
Votes cast “for” the proposal must exceed votes cast “against” the proposal
|
No
|
FOR
|
Amendment to Articles of Incorporation to allow shareholders to amend the By-laws
|
Votes cast “for” the proposal must exceed votes cast “against” the proposal
|
No
|
FOR
|
47
|
Xylem
2017 Proxy Statement
|
Xylem
2017 Proxy Statement
|
48
|
49
|
Xylem
2017 Proxy Statement
|
![]()
XYLEM INC.
1 INTERNATIONAL DRIVE
RYE BROOK, NEW YORK 10573
|
|
WE ENCOURAGE YOU TO TAKE ADVANTAGE OF INTERNET OR TELEPHONE VOTING. BOTH ARE AVAILABLE 24 HOURS A DAY, 7 DAYS A WEEK.
Internet and telephone voting are available through 11:59 PM (ET) the day before the Annual Meeting. Your Internet or telephone vote authorizes the named proxies to vote the shares in the same manner as if you marked, signed and returned your proxy card. If you vote your proxy by Internet or by telephone, you do not need to mail back your proxy card.
VOTE BY INTERNET -
www.proxyvote.com
Use the Internet to vote your proxy. Have your proxy card in hand when you access the website.
VOTE BY TELEPHONE - 1-800-690-6903
Use any touch-tone telephone to vote your proxy. Have your proxy card in hand when you call.
VOTE BY MAIL
Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.
ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS
If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years.
|
|
|
|
|
E21161-P90325
|
|
KEEP THIS PORTION FOR YOUR RECORDS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.
|
DETACH AND RETURN THIS PORTION ONLY
|
XYLEM INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR”
PROPOSALS 1, 2, 3 AND 4
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Vote on Directors
|
|
Vote on Proposals
|
|
For
|
|
Against
|
|
Abstain
|
|
|||||||||||
|
1.
|
Election of six members of the Xylem Inc. Board of Directors.
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
Nominees:
|
|
For
|
|
Against
|
|
Abstain
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
1a
|
|
Curtis J. Crawford, Ph.D.
|
|
¨
|
|
¨
|
|
¨
|
|
2.
|
|
Ratification of the appointment of Deloitte & Touche LLP as our Independent Registered Public Accounting Firm for 2017.
|
|
¨
|
|
¨
|
|
¨
|
|
|
|
1b
|
|
Robert F. Friel
|
|
¨
|
|
¨
|
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1c
|
|
Sten E. Jakobsson
|
|
¨
|
|
¨
|
|
¨
|
|
3.
|
|
Advisory vote to approval the compensation of our named executive officers.
|
|
¨
|
|
¨
|
|
¨
|
|
|
|
1d
|
|
Steven R. Loranger
|
|
¨
|
|
¨
|
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1e
|
|
Surya N. Mohapatra, Ph.D.
|
|
¨
|
|
¨
|
|
¨
|
|
4.
|
|
Management Proposal:
Approval of an amendment to the Company's Articles of Incorporation to Allow Shareholders to Amend the By-Laws.
|
|
¨
|
|
¨
|
|
¨
|
|
|
|
1f
|
|
Jerome A. Peribere
|
|
¨
|
|
¨
|
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For address changes and/or comments, please check this box and write them on the back where indicated.
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Please indicate if you plan to attend this
Meeting
|
|
¨
|
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
Yes
|
|
No
|
|
|
|
|
|
|
|
|
|
|
|
|
(When signing as attorney, executor, administrator, trustee or guardian, give full title. If more than one trustee, all should sign.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Signature [PLEASE SIGN WITHIN BOX]
|
|
Date
|
|
|
|
|
|
Signature (Joint Owners)
|
|
Date
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
![]() |
|
|
|
|
|
PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF XYLEM INC.
FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 10, 2017.
|
|
||||||
|
|
|
|
|
|
|
|
|
|
The shareholder(s) whose signature(s) appear(s) on the reverse side of this proxy form hereby appoint(s) Hannah Skeete and Claudia Toussaint, or either of them, each with full power of substitution as proxies, to vote all shares of Xylem Inc. common stock that the shareholder(s) would be entitled to vote on all matters that may properly come before the Annual Meeting and at any adjournments or postponements. The proxies are authorized to vote in accordance with the specifications indicated by the shareholder(s) on the reverse side of this form. If this form is signed and returned by the shareholder(s), and no specifications are indicated, the proxies are authorized to vote as recommended by the Board of Directors.
In either case, if this form is signed and returned, the proxies thereby will be authorized to vote in their discretion on any other matters that may be presented for a vote at the Annual Meeting and at any adjournments or postponements.
|
|
||||||
|
|
|
|
|
|
|
|
|
|
For participants in a Xylem Retirement Savings Plan:
Under the savings plans, participants are “named fiduciaries” to the extent of their authority to direct the voting of Xylem Inc. shares credited to their savings plan account and their proportionate share of allocated shares for which no direction is received and unallocated shares, if any (together, “Undirected Shares”). Participants under these plans should mail their confidential voting instruction card to Broadridge, acting as tabulation agent, or vote by Phone or Internet. Instructions must be received by Broadridge before 11:59 p.m. (ET), on May 5, 2017. The trustee of the savings plans will vote Undirected Shares in the same proportion as the shares for which directions are received from participants, except as otherwise provided in accordance with ERISA. By submitting voting instructions by telephone or Internet, or by signing and returning this voting instruction card, you direct the trustee of the savings plans to vote these shares, in person or by proxy, as designated herein, at the Annual Meeting.
|
|
||||||
|
|
|
|
|
|
|
|
|
|
The Trustee will exercise its discretion in voting on any other matter that may be presented for a vote at the Annual Meeting and at any adjournments or postponements.
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Address Changes/Comments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(If you noted any Address Changes/Comments above, please mark corresponding box on the reverse side.)
|
|
|
|
||
|
|
|
(Continued, and to be dated and signed on the reverse side.)
|
|
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
Customers
No Suppliers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|